Fluidigm Corporation announced that a new landmark study demonstrates the potential for Imaging Mass Cytometry on the Hyperion Imaging System to transform tissue pathology by identifying cellular signatures within tissue microenvironments that correlate with clinical outcomes. The innovative study suggests highly multiplexed spatial information at single-cell resolution has the potential to improve patient-specific treatment selection in the future. Researchers at the University of Zurich, University of Cambridge and University of Basel conducted the 352-patient study, results of which have been published in Nature. The Hyperion Imaging System is revolutionizing translational and clinical research by providing unprecedented visualization of complex cellular phenotypes and their relationships in the context of cancer, immuno-oncology and immune-mediated diseases. Using the dual capability to perform both mass cytometry and IMC, researchers can deeply profile a wide range of samples from blood to tissues, all on the same system. The published study used the Fluidigm Hyperion Imaging System to simultaneously quantify 35 biomarkers, generating 720 high-dimensional pathology images of tumor tissue from 352 patients with breast cancer for whom long-term survival data were available. Spatially resolved single-cell analysis identified the phenotypes and spatial organization of single cells within the tumor and in the surrounding microenvironment. This enabled deep characterization of breast cancer architecture at single-cell resolution. Key findings from the study include: The Fluidigm Hyperion Imaging System enables single-cell resolution of protein expression profiles and spatial location within a complex tissue, such as breast cancer. Analysis of single-cell protein expression and spatial data identified 14 main clusters containing common cellular subtypes and also identified 18 single-cell pathology (SCP) groups that differed from the traditional pathology-based subtypes and had distinct clinical outcomes between patients and between other SCP subgroups in the same pathology classification and other SCP subgroups with similar cellular composition but distinct architecture.